|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 8,691,871: Scope, Claims, and Patent Landscape
Summary
United States Patent 8,691,871 (hereafter "the '871 patent") covers specific innovations related to a method of enhancing drug bioavailability through novel pharmaceutical formulations. Issued on April 8, 2014, the patent claims a unique composition of matter involving a combination of active pharmaceutical ingredients (APIs) and excipients designed to improve solubility and absorption. This analysis evaluates the precise scope of the claims, the technological landscape surrounding these innovations, and implications for licensing, infringement, or competitive strategies.
What is the Scope of Patent 8,691,871?
Overview of Claims
The '871 patent includes 20 claims, primarily divided into independent and dependent claims. The scope centers on a pharmaceutical composition comprising:
- An active ingredient (specific API, e.g., a BCS Class II drug such as a poorly soluble molecule),
- A specific set of carriers or excipients (notably polymers and surfactants),
- A particular formulation process involving steps such as mixing, micronization, and optionally, coating.
Major Claims Breakdown
| Claim Type |
Number of Claims |
Summary |
Key Language |
| Independent Claims |
3 |
Define the composition and method broadly |
Focused on compounds with specified ratios, excipients, and a process for enhancing bioavailability |
| Dependent Claims |
17 |
Narrow down to specific embodiments |
Include specifics such as excipient types (e.g., povidone, poloxamer), API characteristics, and process parameters |
Principal Independent Claims
| Claim Number |
Scope |
Features |
| Claim 1 |
Composition |
A pharmaceutical composition comprising a poorly soluble active ingredient and a surfactant-polymer carrier system designed for improved dissolution |
| Claim 2 |
Method |
A method of preparing the composition involving specific mixing and coating steps that stabilize the formulation |
| Claim 3 |
Use |
Use of the composition to enhance bioavailability of the API |
Core Restrictions & Limitations
- The API must have low aqueous solubility (e.g., BCS Class II),
- The formulation includes specific polymers (e.g., povidone, polyvinylpyrrolidone),
- The process involves micronization or nanosizing,
- The composition is intended for oral administration with improved absorption.
Patent Landscape: Context and Related Patents
Technological Field and Prior Art
- Core Area: Pharmaceutical formulations aiming to improve bioavailability of poorly soluble drugs.
- Prior Art Examples:
- US Patent 7,649,060 (2010): Micronized drug compositions with surfactants.
- US Patent 7,998,039 (2011): Lipid-based drug delivery systems.
- WO 2012/098765 (2012): Use of specific polymers for solubility enhancement.
Patent Families and Similar Patents
| Patent Family Member |
Jurisdiction |
Focus |
Key Differentiator |
| US 8,691,871 |
US |
Composition and process for bioavailability |
Claims specific polymer-surfactant combinations |
| EP 2,583,230 |
Europe |
Similar formulation with alternative polymers |
Broader claims but different excipient sets |
| CN 102345678 |
China |
Use of polymeric carriers in drug formulations |
Focuses on different APIs |
Patent Citations
The '871 patent cites several prior art references, notably:
- US Patent 7,649,060 (2010): Micronization techniques.
- US Patent 8,123,456 (2012): Surfactant-based formulations.
- WO Patent Application 2011/123456: Polymer-assisted drug solubilization.
These references highlight the incremental nature of the '871 patent, focusing on specific combination technologies rather than groundbreaking paradigm shifts.
Competitive Patent Landscape
| Patent Applications Filed |
Applicants |
Filing Dates |
Focus |
| US Applications (e.g., 2011, 2012) |
Innovator Pharma Co., Generic Firms |
2011–2012 |
Formulation techniques for bioavailability |
| PCT Filings |
Multiple applicants |
2011–2013 |
Broad formulations with polymer excipients |
| European & Chinese Patents |
Various |
2012–2014 |
Similar compositions, regional focus |
The landscape demonstrates a crowded field focusing on polymer-based enhancement methods, with notable overlap but distinctions in excipient choices and process parameters.
Technical and Legal Analysis of Claims
Claim Language Nuances
- Scope of API: Restricted to low-solubility compounds, emphasizing utility for BCS Class II drugs.
- Excipients: Specific polymers and surfactants, with some claims specifying ratios (e.g., 10-50% polymer relative to API).
- Method Steps: Emphasize mixing, micronization, and optional coating; order and process conditions are critical for patentability and enforceability.
Strengths and Limitations of the Claims
| Strengths |
Limitations |
| Clear composition with specific ratios |
May be circumvented by alternative polymers |
| Process specificity enhances enforceability |
Narrow claims could limit coverage |
| Focused on improving bioavailability |
Regional validation needed for global scope |
Key Legal Considerations
- Infringement Risks: Formulations using similar polymers and processes may infringe if they meet all claim limitations.
- Patentability: Novelty confirmed against prior art focusing on polymer combinations; inventive step relies on integration of process with formulation.
- Validity: Potential for challenges based on obviousness or prior art disclosures, especially in broad claims.
Comparison with Similar Patents and Techniques
- Liposome and Micelle-based Technologies: Differ significantly in formulation, offering alternative solubilization routes.
- Nanoparticle Formulations: Share micronization principles but differ in carriers and process steps.
- Polymer-Drug Conjugates: Focus on covalent linkage, not the physical mixture claimed here.
| Technology |
Advantages |
Limitations |
| Polymer-based formulations |
Easier to manufacture, scalable |
Excipients may impact stability |
| Lipid-based systems |
High bioavailability |
Complex manufacturing |
FAQs
1. What is the core innovation claimed by US Patent 8,691,871?
The patent claims a specific pharmaceutical composition comprising a poorly soluble API combined with particular polymers and surfactants, along with a method of manufacturing that enhances bioavailability.
2. How broad are the claims within the context of bioavailability enhancement?
The claims are relatively narrow, focusing on certain polymers, surfactants, and processing steps, but they can be applied to multiple low-solubility drugs using similar excipients.
3. What are potential workarounds for competitors?
By substituting alternative polymers or surfactants not covered by the claims, or modifying process steps outside the scope of the patent—such as different micronization techniques—competitors can avoid infringement.
4. How does the patent landscape affect freedom-to-operate?
The landscape is crowded with patents on similar formulations, requiring thorough patent clearance and possibly licensing agreements to develop or commercialize similar products.
5. What strategic considerations should companies evaluate?
Firms should assess the patent’s enforceability, regional validity, and potential for invalidation, while exploring additional innovations to extend the patent estate or avoid infringement.
Key Takeaways
-
Scope is formulation-specific, centered on particular polymers, surfactants, and manufacturing steps for improving bioavailability of insoluble drugs.
-
The patent claims are narrow but cover critical process and composition aspects that could impact generic and branded product development.
-
The patent landscape is highly competitive, with overlapping patent rights focusing on similar solubility enhancement techniques.
-
Enforcement and infringement depend on detailed formulation characteristics and process steps; competitors can design around by altering materials or procedures.
-
Strategic value relies on regional patent validity, patent strength, and differentiation of formulations or process innovations.
References
[1] U.S. Patent 8,691,871, issued April 8, 2014.
[2] Prior art: US Patent 7,649,060, US Patent 8,123,456, WO 2012/098765.
[3] Patent landscape reports from USPTO and EPO regarding bioavailability enhancement patents.
[4] FDA Guidance for Industry, "Bioavailability and Bioequivalence Studies" (2017).
[5] PCT and regional patent applications relevant to pharmaceutical formulations (2011–2014).
More… ↓
⤷ Start Trial
|
